# Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients

> **NCT06911489** · PHASE1 · RECRUITING · sponsor: **Chengdu New Radiomedicine Technology Co. LTD.** · enrollment: 132 (estimated)

## Conditions studied

- Solid Tumor Malignancy

## Interventions

- **DIAGNOSTIC_TEST:** 68Ga-NRT6020 Injection
- **DRUG:** 177Lu-NRT6020 Injection (stage 2)
- **DRUG:** 177Lu-NRT6020 Injection (stage 3)

## Key facts

- **NCT ID:** NCT06911489
- **Lead sponsor:** Chengdu New Radiomedicine Technology Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-29
- **Primary completion:** 2027-10
- **Final completion:** 2027-12
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06911489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06911489, "Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06911489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*